FDA Says Fusion’s Claims For Facial “Lift” Products Make Them Drugs
This article was originally published in The Rose Sheet
Executive Summary
FDA expects Fusion Brands' written response to an April 24 warning letter within the next two weeks, the agency told "The Rose Sheet" May 30
You may also be interested in...
How Not To Cross FTC: Attorneys Offer Advice For Cosmeceutical Marketers
Claims for cosmeceuticals referred by the National Advertising Division go to the same place on the Federal Trade Commission's list of priorities as other disputed claims - straight to the top
How Not To Cross FTC: Attorneys Offer Advice For Cosmeceutical Marketers
Claims for cosmeceuticals referred by the National Advertising Division go to the same place on the Federal Trade Commission's list of priorities as other disputed claims - straight to the top
Attorney Discusses Cosmetic Trespasses On Drug Turf Leading To FDA Action
The line that divides drugs from personal care is "fuzzy," but companies can begin to understand what marketing claims are acceptable to FDA by learning from the mistakes of others, Ivan Wasserman, partner at Manatt, Phelps & Phillips, suggests